Schroder Investment Management Group Lowers Stake in Hologic, Inc. (NASDAQ:HOLX)
Schroder Investment Management Group lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 96.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 26,809 shares of the medical equipment provider’s stock after selling 642,049 shares during the period. Schroder Investment Management Group’s holdings in Hologic were worth $2,171,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in HOLX. Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of Hologic by 98,061.1% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 22,086,241 shares of the medical equipment provider’s stock worth $1,788,323,000 after purchasing an additional 22,063,741 shares during the period. Macquarie Group Ltd. boosted its position in shares of Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after purchasing an additional 4,363,687 shares during the period. Wellington Management Group LLP boosted its position in Hologic by 80.0% in the 1st quarter. Wellington Management Group LLP now owns 8,984,757 shares of the medical equipment provider’s stock valued at $725,070,000 after buying an additional 3,992,822 shares during the period. Norges Bank purchased a new position in Hologic in the 4th quarter valued at approximately $175,900,000. Finally, Envestnet Asset Management Inc. boosted its position in Hologic by 506.3% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,711,592 shares of the medical equipment provider’s stock valued at $29,345,000 after buying an additional 1,429,300 shares during the period. Hedge funds and other institutional investors own 92.64% of the company’s stock.
Insider Buying and Selling at Hologic
In other Hologic news, insider Essex D. Mitchell sold 7,500 shares of Hologic stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $71.85, for a total value of $538,875.00. Following the transaction, the insider now directly owns 12,827 shares in the company, valued at $921,619.95. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.66% of the stock is currently owned by company insiders.
Hologic Price Performance
Shares of NASDAQ:HOLX opened at $71.15 on Friday. The company’s fifty day moving average price is $69.39 and its 200 day moving average price is $74.66. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.47 and a quick ratio of 2.95. The firm has a market capitalization of $17.08 billion, a P/E ratio of 38.88, a P/E/G ratio of 2.31 and a beta of 1.02.
Hologic (NASDAQ:HOLX – Get Free Report) last posted its quarterly earnings data on Thursday, November 9th. The medical equipment provider reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.05. The company had revenue of $945.30 million for the quarter, compared to analyst estimates of $940.00 million. Hologic had a net margin of 11.31% and a return on equity of 19.12%. Hologic’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the previous year, the business posted $0.82 earnings per share. As a group, sell-side analysts predict that Hologic, Inc. will post 3.99 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have commented on HOLX shares. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, November 27th. Raymond James decreased their price target on shares of Hologic from $95.00 to $85.00 and set an “outperform” rating for the company in a research report on Wednesday, October 18th. Morgan Stanley decreased their price target on shares of Hologic from $86.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, November 13th. Needham & Company LLC decreased their price target on shares of Hologic from $95.00 to $83.00 and set a “buy” rating for the company in a research report on Thursday, October 26th. Finally, UBS Group decreased their price target on shares of Hologic from $91.00 to $78.00 and set a “neutral” rating for the company in a research report on Thursday, November 16th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.58.
View Our Latest Research Report on Hologic
Hologic Company Profile (Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women’s health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Hologic, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Hologic wasn’t on the list.
While Hologic currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.